glp-1 breast cancer The Impact and Safety of GLP‐1 Agents and GLP-1 use linked to lower

The issue of obesity and insulin resistance prompted the design of a number of studies investigating the effects of antidiabetic drugs in PCOS, as reported in recent and very exhaustive reviews on the available clinical trials on glucagon-like peptide 1 receptor agonists (GLP-1RA) in PCOS [21, 23, 24]

While anabolic or anti-catabolic agents - especially myostatin/activin pathway inhibitors - show promise, translation into improved patient-centered outcomes is not yet established (Table 3)

But always speak to a professionalother conditions, like inner ear issues, can cause similar symptoms

Front Endocrinol (Lausanne) 14 , 1199291